Key Highlights

  • AXT shares surged 29% after reporting record indium phosphide Revenue of $30.7 million tied to AI Data Center optical connectivity, capping a two-day gain of 63.5% including a supply-deal announcement.
  • The company guided September-quarter revenue to roughly $66 million, about 70% above analyst consensus, with gross Margin reaching 44.9% versus negative 6.4% just five quarters earlier.
  • Revenue growth remains capped by individual Chinese export permits required for every indium phosphide order, with a key US-directed export restriction suspension expiring November 27, 2026.

A 63% two-day move, not a 29% one

AXT ( Nasdaq :AXTI) closed at $60.43 on Friday 31 July 2026, up 28.74%, on 29.6 million shares. The framing that matters is the two-day sequence. On 29 July the company announced a six-year Supply agreement with Lumentum running to the end of 2031, and the stock rose 26.97% on 30 July, from $36.97 to $46.94. Second-quarter results landed after that close. The cumulative two-day gain was 63.5%.

The headline claims survive verification precisely. Indium phosphide revenue was $30.7 million in the June quarter. Chief executive Morris Young told the market it was "our highest quarterly indium phosphide revenue to date", and chief financial officer Gary Fischer called it "the highest in our company's history". Young attributed the Demand directly to AI: "the deployment of optical connectivity in AI data center is accelerating as hyperscalers scale GPU dense architectures." Total quarterly revenue of $47.59 million was also an all-time record.

One clarification is owed to readers. The 31 July move was driven at least as much by guidance as by the record quarter. AXT guided the September quarter to roughly $66 million of revenue against consensus near $38.8 million, and non-GAAP Earnings of $0.30 to $0.32 a share against $0.11. Needham upgraded to Buy with a $90 target the same morning. Short interest at 17.3% of shares outstanding will have amplified the rest.

What AXT makes

AXT, based in Fremont, California, produces compound semiconductor substrates, the wafers on which other companies build devices. Indium phosphide, 64.5% of June-quarter revenue, goes into the lasers and silicon photonics inside 800G and 1.6T optical transceivers, the components that move data between servers in AI data centres. Gallium arsenide, at $6.6 million, serves lasers, LEDs and wireless. Germanium, at $272,000, is now immaterial. Raw-material joint ventures producing purified gallium and pyrolytic boron nitride crucibles contributed $10.0 million.

All wafer Manufacturing takes place in China, through the majority-owned Subsidiary Beijing Tongmei. Third-party research puts the indium phosphide substrate market at 80% to 90% controlled by three companies (Sumitomo Electric, JX Metals and AXT) though AXT's own share is not disclosed. In the June quarter the top five customers accounted for around 30% of revenue with none above 10%.

The quarter itself

Revenue of $47.59 million was up 164.8% year on year and 77% sequentially. Gross margin reached 44.9%, against 8.0% in the same quarter of 2025 and negative 6.4% as recently as the March 2025 quarter. Operating Income was $10.42 million and Net Income $11.13 million, or $0.17 a share on a GAAP basis and $0.19 adjusted, against consensus near $0.07.

This was AXT's first profitable quarter after seven consecutive losses. Full-year 2025 revenue fell 11.2% to $88.3 million with a net loss of $21.3 million. Indium phosphide Backlog is described as well over $100 million. Cash and equivalents stood at $412.17 million with total cash and investments of $748.8 million, following an April 2026 Equity offering of 8,560,311 shares at $64.25.

The constraint nobody should overlook

AXT's revenue is not purely a function of demand. Since 4 February 2025, indium phosphide substrates have required an individual Chinese export permit for every customer order. The company received its first such permit in late June 2025. In the December 2025 quarter it received fewer than expected and missed its own revenue guidance as a result.

The September guidance is explicitly bounded by this. Fischer said the company has "approximately $66 million in revenue that can be realized in Q3". Meaning Volume already permitted or not requiring permits, with further approvals framed as upside. Separately, China's US-specific restriction on gallium and germanium exports was suspended in November 2025, but only until 27 November 2026. That is a hard date on the calendar, and the underlying legal framework remains in place. North American revenue has already collapsed to roughly 1% to 2%, from 8% in 2024, under US tariffs the company's Annual Report records reaching 70%.

The bull case

Gross margin moved from negative 6.4% to 44.9% in five quarters, and incremental gross margin on the sequential revenue increase was around 65%. That is what Operating Leverage looks like in a fixed-cost substrate Business finally running near capacity. Backlog above $100 million covers more than two quarters and is still building. Two named customers (Lumentum and Coherent) have committed prepayments against future shipments, including $43.5 million due from Lumentum within 30 business days of signing. Management targets roughly $60 million of quarterly indium phosphide capacity leaving 2026 and $130 million leaving 2027, and says the near-term expansion requires little additional Capital spending.

The bear case

Start with the valuation the screener reports: a trailing price-to-earnings ratio of 3,131 on $0.02 of trailing twelve-month diluted earnings. That figure is arithmetically correct and it tells you the company has one profitable quarter behind it and a $3.9 billion Market Capitalisation in front of it. On trailing revenue of $125.5 million the stock trades at roughly 31 times sales. Reaching the forward multiple of about 38 requires annualising a quarter that has not happened yet and then assuming growth beyond it.

The 2027 capacity target of $130 million a quarter implies roughly $520 million of annualised indium phosphide revenue, about four times the entire company's current trailing revenue, from one product line, within eighteen months, partly via greenfield construction. Management's own gross margin target, in Fischer's words, is "a number that begins with a 4", and the company is already at 45.0%, implying limited further margin expansion is guided. Meanwhile Tongmei's four-year attempt at a Shanghai STAR Market listing was withdrawn in June 2026, triggering Redemption rights over roughly $49 million held by eleven Chinese Private Equity funds, with a Hong Kong listing now around a year away.

Two further facts belong in any balanced account. AXT sold $550 million of equity at $64.25 in April, above Friday's close. And even after gaining 28.74%, the stock remains roughly 58% below its 52-week high of $143.16, set in late May before a 74% drawdown into the end of July.

What to watch

This was a genuine operational inflection, and the headline claims hold. But the move was two days long, guidance did more work than the record quarter, and the September number is capped by permits the company does not control. The dates that matter are 27 November 2026, when China's suspension of its US-directed restriction expires, and whatever incremental permits arrive before then. The clearest upside is a backlog above $100 million converting at 45% margins. The clearest downside is that a company gated by a foreign export bureaucracy is being valued as though it is not.

Key Investor Takeaways

  • Both headline claims verify: Indium phosphide revenue of $30.7 million in the June quarter was the highest in company history, confirmed by both the chief executive and chief financial officer, and management attributed demand directly to AI data-centre optical connectivity.
  • The move was two sessions, not one: AXT rose 26.97% on 30 July after announcing a six-year Lumentum supply agreement, then 28.74% on 31 July after results; a cumulative 63.5% from $36.97.
  • Guidance did more work than the record quarter: September-quarter guidance of roughly $66 million in revenue and $0.30 to $0.32 in non-GAAP earnings compared with consensus near $38.8 million and $0.11.
  • The first profitable quarter after seven losses: Gross margin reached 44.9% against negative 6.4% in the March 2025 quarter, producing net income of $11.13 million after full-year 2025 losses of $21.3 million.
  • Chinese export permits gate the revenue: Every indium phosphide order has required an individual Chinese export permit since 4 February 2025. AXT missed its own December-quarter guidance when permits arrived slowly, and September guidance covers only volume already permitted.
  • A hard date sits on the calendar: China's suspension of its US-specific gallium and germanium export restriction expires on 27 November 2026. North American revenue has already fallen to roughly 1% to 2% from 8% in 2024.
  • The valuation carries no margin for error: A trailing price-to-earnings ratio of 3,131 on $0.02 of trailing diluted earnings, and roughly 31 times trailing sales, on a single profitable quarter.

Upcoming Catalysts

  • Third-quarter 2026 results; no company-confirmed date as of 1 August 2026. Third-party estimates point to late October, and AXT typically issues a separate scheduling announcement first.
  • Incremental Chinese export permits beyond the volume already covered by the roughly $66 million September guidance; explicitly flagged by management as upside.
  • Expiry on 27 November 2026 of China's suspension of Announcement No. 46, the US-specific restriction on gallium and germanium exports. This is the single hardest-dated binary risk on the calendar.
  • First Lumentum deposit of $43.5 million, contractually due within 30 business days of the 29 July 2026 agreement; approximately early September 2026. A second $43.5 million has terms to be determined during 2028.
  • Tongmei's Hong Kong listing, which the chief financial officer said "will likely take about a year" following Withdrawal of the Shanghai STAR Market application in June 2026.
  • Resolution of redemption rights over roughly $49 million held by eleven Chinese private equity funds in Tongmei, triggered by the STAR Market withdrawal. No deadline has been disclosed.
  • Capacity milestones: management targets roughly $60 million of quarterly indium phosphide capacity exiting 2026 and $130 million exiting 2027.

Principal Risks

  • Chinese export licensing is a revenue gate rather than a background risk. Every indium phosphide, gallium arsenide and germanium order requires an individual permit, and the December 2025 quarter demonstrated the downside when permits arrive slowly.
  • The 27 November 2026 expiry of China's suspension of its US-directed gallium and germanium restriction. Non-renewal would restore an outright restriction.
  • All manufacturing sits in China, in a materials category central to US-China technology tension, with no geographic Diversification and no announced plan for one.
  • Near-total loss of the North American market; roughly 1% to 2% of revenue, down from 8% in 2024, under US tariffs the annual report records reaching 70%.
  • Single-product concentration: indium phosphide is 64.5% of revenue and effectively the entire growth story. Gallium arsenide is flat and germanium is immaterial.
  • Valuation leaves no margin for error; roughly $3.9 billion of market capitalisation against $125.5 million of trailing revenue, $0.02 of trailing diluted earnings and one profitable quarter.
  • Capacity targets require roughly four times revenue growth in eighteen months, with the 2027 step dependent on greenfield construction and Yield replication in a notoriously difficult crystal-growth process.
  • Management's own gross margin target is described as a number beginning with a four, and the company is already at 45.0%; implying limited guided margin expansion from here.
  • Tongmei redemption overhang of roughly $49 million following the withdrawn Shanghai listing, with a Hong Kong alternative around a year away.
  • Dilution: shares outstanding rose from 55.6 million in March 2026 to roughly 64 to 65 million after the April equity raise, which was priced at $64.25; above the 31 July close.
  • Extreme Volatility and crowded positioning: a five-year Beta near 1.97, a 74% peak-to-trough decline between late May and late July 2026, and short interest above 17% of shares outstanding.
  • Disclosure quality: product-line revenue, guidance and capital spending are given orally on earnings calls rather than in the written release, and capital-spending figures have been inconsistent between calls.

Conclusion

AXT's rally reflects a genuine operational inflection: gross margin swung from negative to nearly 45% in five quarters, and AI-driven demand for optical connectivity is real and accelerating. But the company's growth remains gated by Chinese export permits it doesn't control, and management's own September guidance is explicitly bounded by what's already been approved to ship. A trailing price-to-earnings ratio above 3,000 reflects one profitable quarter, not an established trend. The November 27 expiration of the current export suspension is the date that matters most for whether this becomes a sustained re-rating or a single strong quarter.

This article is for informational purposes only and does not constitute Investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.